Epigenetics: An Emerging Target Class for Drug Screening By Dr John Comley Heightened awareness of the potential importance of epigenetic targets in many disease areas, and growing vendor interest in developing new assays to screen DNA methylation and histone modifications encouraged HTStec to undertake market research in… Read More
The Benefits Of Drug Repositioning By Dr Aris Persidis Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy… Read More
Balancing A Biologics Pipeline Portfolio By Dr Herren Wu Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology. Discovering and developing an innovative, first-in-class biologic has the potential… Read More
High Throughput Screening Systems: Impact of Reliability on Downtime and Drug Discovery By Dr John Comley This article reports the results of a survey on the reliability of automated HTS assay systems and the effect of reliability on output. Evidence supporting the view that high throughput screening (HTS)… Read More
Moving Forward With Label-Free Technology By Dr Jennifer Hartigan, Cindy Liu and William Downey Label-free technology is gaining acceptance and opening doors for new drug discovery. Relatively new in the well-established world of high throughput screening (HTS), label-free technology provides opportunities for probing biomolecular interactions without spatial-interference, auto-fluorescent… Read More
Assessing the Value of R&D Partnerships By Dr David A Pardoe, Dr Jackie Hunter MBE, Dr Robert M Cooke and Dr Paul Barrett In response to the need to increase the return on investment in R&D, many large Pharma companies are shifting from an internal fixed resource model… Read More
R&D Open Verdict? By Dr Kay Wardle As pharmaceutical companies begin to shift from in-house R&D to external partnerships and ‘open innovation’, the traditional drug discovery model may soon be a thing of the past. In this article we explain what is driving these changes and what the… Read More
Neutron Scattering Provides Unique Insights for Drug R&D By Dr Martyn Bull Drug discovery and development is a long and expensive process. Techniques, such as computer modelling, that make the search for promising candidates easier are usually taken up enthusiastically. Neutron scattering,… Read More
New Mechanisms and Expanded Indications for Biologic Therapies: a perspective on immunology research and development By Dr Susan B. Dillon Over the past decade, the introduction of biologic therapies has had a profound impact for millions of patients with immune-mediated arthritides, inflammatory bowel diseases and plaque psoriasis. Read More
Current Trends in Label-Free Drug Discovery Technologies By Philip Rawlins Drug Discovery Label-free technologies have been used throughout drug discovery for the detection and characterisation of molecular interactions. The implementation of automated systems, increased sensitivity and the development of new technologies have recently broadened the use of… Read More
Mass Spectrometry is a mature technology predicated on a premise demonstrated almost a century ago. It is widely used in most scientific disciplines involving basic research or industrial endeavours, that require accurate and precise measurement of elemental and molecular components. More recently it… Read More
Bulk Reagent Dispensers: Ubiquitous liquid handling tool for microplate filling By Dr John Comley The initial success of the bulk reagent dispenser (BRD) as an automated liquidhandling product can be attributed to its simplicity and low cost. Its current role as an essential dispensing tool in those… Read More
Overcoming Bottlenecks in Drug Discovery By Dr Trevor Perrior Developing a new drug is an expensive and time-consuming process. The best current estimate puts the cost of developing a single new drug at close to $1 billion. After a drug candidate has entered… Read More
Is the Pharmaceutical Industry Open For Innovation? By Dr Jackie Hunter CBE Open innovation is the hot topic in many industries and this approach has the potential to make a radical difference to the costs of drug discovery and development in the pharmaceutical industry. But there are… Read More
High Throughput Flow Cytometry for Discovery at UNMCMD and the NIH Molecular Libraries Initiative By Dr Larry A. Sklar and Dr Bruce S. Edwards Commercial flow cytometers became widely established in research and clinical laboratories in the 1980s. Once the domain of immunologists and hematologists for cell… Read More
Biomarkers Make Their Mark on Current Research and Drug Development Trends By Stephane Parent and Dr Gregory Cosentino Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion… Read More
